SBS Filipino Radio Program, Friday 6 June 2025
The short film 'A Long Drive' aims to tell the story of Filipinos striving for a better life in Australia.
For Retro Radio, take a look back at the interview with Anne Curtis from 2008. SBS Filipino
06/06/2025 43:54 📢 Where to Catch SBS Filipino
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Australian
25 minutes ago
- The Australian
Health Kick Podcast: Imagion Biosystems
Stockhead's health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim speaks with Imagion Biosystems (ASX:IBX) chairman Robert Proulx and company advisor Dr Leonardo Kayat Bittencourt. Did you know that X-ray technology was invented more than a century ago? You can thank German scientist Wilhelm Conrad Röntgen for that. Since then, diagnostic technology in the healthcare sector has made leaps and bounds, and one of the companies at the forefront is Imagion Biosystems. Tune in to hear how IBX is accelerating early detection of cancer, how their MagSense Technology works, and more. This podcast was developed in collaboration with Imagion Biosystems, a Stockhead advertiser at the time of publishing. The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.
ABC News
an hour ago
- ABC News
The price of perfectionism for women
In the early 2000s, Sheila Vijeyarasa was a powerful woman climbing the corporate ladder. At least that's how it looked from the outside. In reality, the now 48-year-old from Sydney/Gadigal Country says she spent 20 years dealing with "crippling amounts of anxiety and depression". All because she was a perfectionist. Sheila, who worked in accounting and publishing, would work ridiculously long hours — sometimes seven day a week — to try to satisfy her own high standards. "I wanted someone to say, 'you're amazing. You're the best.'" She says her strive for perfectionism meant her social life and relationships suffered, along with her mental health. Especially if she ever made a mistake. "I fell into a depression and anxiety. I stopped eating, I stopped sleeping, I stopped coping," she recalls about one particular incident. When you hear the term perfectionism, you might think of people who have achieved big goals, like winning gold at the Olympics. Or maybe you picture someone with a perfectly organised pantry, categorised and labelled. But real perfectionism is not necessarily about achievement or structure, and can be debilitating and all-consuming, as ABC podcast Ladies We Need to Talk discovered. While high achievers can also be perfectionists, there is a difference between pursuing excellence and pursuing perfection, explains Eileen Seah, a self-described "recovering perfectionist" and clinical psychologist. She is based in Sydney and specifically treats people with perfectionist tendencies. "Pursuing perfection is unattainable because in reality there's always going to be stuff that isn't going to be perfect," Ms Seah says. "Whereas excellence, it's having high standards, but also being very contextual, recognising there's certain limitations you should be adapting to." Perfectionism, which Ms Seah describes as a personality trait, often sits alongside anxiety, depression, disordered eating and compulsive behaviour. She says perfectionists are often workaholics and very detail-orientated — but also procrastinators. "You get people who are extremely paralysed by the fear of failure. "They avoid the tasks that they need to do … because they might be judged for their performance." Perfectionism can show up at any stage of life, such as school and university, work, and parenting. "To be constantly feeling the need to optimise, to do better, and not actually ever feeling that you're good enough … it's tiring, exhausting." Sheila says her earliest memories of perfectionism were in school. "I think this is a South-East Asian thing … an immigrant thing … but making a mistake just felt very scary. "There was no maliciousness behind my parents' intentions … they wanted me to be the best, because which parent doesn't want their child to be the best? "I was expected to perform at a high level [at school] … it was being in the top 1 per cent, it was topping exams, getting 100 per cent." And perfectionism hasn't just ruled Sheila's schooling and working life. Despite doing better in her mid-40s after confronting her perfectionism, those traits made a comeback during her experience with infertility. "I got all the herbs, the acupuncture, [the] best naturopath. I was like, let's see if we can do the MBA of the fertility journey. "And it was round after round, after round, and my mental health definitely declined." At 46, Sheila had to surrender her idea of a "perfect pregnancy" with her own egg, and tried getting pregnant using a donor egg. "It felt unnatural at the time. Yet my vision to be a mother was so strong. "I had to go through an immense amount of grief to let go of that perfect version of me that wanted to be a mother in a certain way." Like Sheila, 37-year-old Caroline Zielinski from Melbourne/Naarm remembers her perfectionism starting in school. "I remember being sick and Mum saying 'You should stay home'. And I remember crying and saying, 'No, I have to go in because I'll miss a day. And that means I won't learn'." Perceived failures also stay with her for a long time, like when she missed out on a dream job in her 20s. "Back then, pressure would break me. I think I cocked up the interview. I was so stressed, like I was so anxious because I wanted it so badly. "It devastated me for … a good 10 years." In her 20s, Caroline started seeing a psychologist hoping to address her perfectionism. "He lent me these lovely books, about kindness and accepting yourself as you are. "And I just remember reading them and going, 'Oh, well, it's a nice fairytale'. "He really tried to get me to be kind, but I ended up just abandoning that. I had a couple of sessions with him, and I just thought he was ineffective." This is a common story for people seeking support with perfectionism, explains Ms Seah. "Perfectionists [can] have very high standards that they place on other people. "The expectation that the therapist is going to fix them, and fix them quickly, [is] one of the common things I've encountered." Caroline says a "win or lose" perspective shapes so many parts of her life. "I often say, if you're going to do something, do it well or don't do it at all. She finds downtime difficult, because every moment must be optimised. "Like when I go on holidays, you've got to go and do hiking and hike the bigger mountain and push yourself a bit." Caroline also struggles when it comes to playtime with her three-year-old. "I built her a fairy playground out of all these different toilet paper rolls and stuff. "But it gets to a point where I'm like, 'You're doing it wrong, Evie'. "She just wants to play." Sheila, who ended up having a baby using a donor egg, says becoming a mum has "cured" her perfectionism. "This morning he had porridge all over his hands and he wanted a hug. And I was wearing this suit. "And I let him hug me … I'm not missing out a single hug. "I fought so hard to have [him]. And every moment with him is a miracle. I savour every delicious moment." Sheila says life looks totally different to when she was ruled by perfectionism. "There's honey dripping down the side and there's 50 teaspoons over there, and there's Lego and wet towels on the floor. "And it is like, little brave acts. It is little steps every single day. "It's been 20 years in the making, and I have a beautiful marriage, the messiest house, the most awesome son, because I honestly dealt with my perfectionism." Caroline says she's determined to get better at letting things go for her daughter's sake. "I do need to get on top of it because I don't want to pass this onto Evie."
News.com.au
2 hours ago
- News.com.au
Health Check: Cancer drug developers drive further positive Car-T results
Imugene and Chimeric have unveiled further promising results for their Car-T immune-oncology assets Rhythm Biosciences shares soar 18% on kit validation results While investors are picky, equity dollars continue to flow There's a long drive ahead, but Imugene (ASX:IMU) and Chimeric Therapeutics (ASX:CHM) are heading in the right direction with their Car-T therapies that trick up the body's T-cells to be better cancer fighters. Imugene shares this morning leaped 10%, after the company reported two additional 'partial responses' in its phase 1b trial. The study aims to combat relapsed diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer. Imugene's Car-T therapy, azer-cel, could result in the first 'off the shelf' Car-T treatment derived from donor cells (rather than the patient). The trial tally now stands at six 'complete responses' and five partial responses. A complete response is disappearance of signs of cancer – tentatively known as a cure. A partial response is a cancer reduction of at least 50%. In all, the trial has achieved an overall response rate of 79%. On July 14 Imugene said nine out of 12 patients had responded, prompting a circa $37 million capital raising. The first patients dosed (last year) remain cancer free at 15 months. They had not responded to several therapy attempts. The trial is underway at ten US sites and six local sites, including Sydney's Royal Prince Alfred Hospital. Cells are 'hard at work' Chimeric reports 'encouraging early results' after moving to a stronger dose in its phase I/II study. The trial tests the company's Car-T candidate CHM CDH17. Chimeric reports one patient with stable disease and "anti-tumour activity", with the lesion shrinking by 12%. The boffins define stable disease as no change in tumour size, or up to 30% shrinkage. One patient from the first dose cohort remains with stable disease eight months after dosing, with an 18% shrinkage. 'This is great progress,' says Chimeric CEO Dr Rebecca McQualter. 'We can see the cells are hard at work to more data'. The trial has enrolled patients with advanced colorectal cancer, gastric cancer and intestinal neuroendocrine tumours. CHM CDH17 targets CDH17, a cancer biomarker 'associated with poor prognosis and metastases in the most common gastrointestinal tumours'. Chimeric expects to enrol 15 patients in the phase I part of the study, with an expanded cohort for phase II. Rhythm's test validation is in the groove Rhythm Biosciences (ASX:RHY) shares today surged a sector-leading ing 18%, on further validation results of the company's Colostat bowel cancer assay. Having received its first kits from the manufacturer for final internal testing, the company tested them on new blood samples from patients with no bowel cancer at any of the stages (one to four). 'This study was critical as the initial intended use of Colostat is for symptomatic patients who could well have early and late-stage disease,' the company says. While Rhythm will complete further studies, the data on 300 patient samples shows that Colostat is equally effective at detecting bowel cancer across all stages. Rhythm will apply to the local National Association of Testing Authorities to have Colostat approved under the common-used laboratory-developed route. Lung imager breathes easier with deep-pocketed backer Friday's keen investor response to lung imager 4D Medical's 4D Medical's (ASX:4DX) funding arrangement with ProMedicus (ASX:PME) no doubt has to do with the mere 'vibe' of the latter taking an interest in the market minnow. In its first tie up with a listed peer, the $30 billion market cap Pro Medicus has extended a $10 million 'hybrid debt and equity loan' to 4D Medical. The duo don't compete with each other. 4D Medical will use the funds to develop its product pipeline and advance a US Food and Drug Administration (FDA) marketing application. This is for the company's ventilation perfusion product, for use in computed tomography. The loan attracts 12.5% interest and is repayable in cash and 'shares valued at the same amount as the cash repayment'. The deal is non-dilutive if the share price remains where is it, with 'upside alignment' for both parties if they perform strongly over the next two years. 4D also reported customer receipts of $1.61 million for the June quarter, up 19%, taking full-year receipts to $12 months to $5.38 million (up 87%). The company undertook 74,000 scans for the quarter, up 105% year on year. 4D had outflows of $9.47 million, down 16% compared with the March quarter. The company ended June with cash of $9.9 million, with a $6 million R&D tax refund due 'in coming weeks'. 4D Medical shares surged 30% on Friday and edged up a further 10% today. Spare us a dime? Other life companies are bringing in the dollars via traditional equity means. The developer of a non-radiation-based imaging for breast and other cancers, Imagion Biosystems (ASX:IBX) has raised $3.5 million in a two-tranche institutional placement. The price was 1.5 cents per share, a 10% discount. The funds will support Imagion's proposed phase II US trial for Her-2 breast cancers. Nyrada (ASX:NYR) has raised $8.25 million via a placement. The company is developing Xolatryp, which blocks a certain ion channel to protect key cells in vital organs when under stress. This could be after a blood clot or reperfusion (the sudden flow of blood returning to an organ or tissue). Nyrada is preparing for a phase IIa acute myocardial infarction trial and has nearly finished a phase I cardioprotection study. Kiwi diagnostics house Pacific Edge (ASX:PEB) has raised NZ$20.7 million in a placement and share purchase plan, having targeted NZ$20 million. US authorities recently cancelled reimbursement of the Pacific Edge's bladder cancer test Cxbladder, but the company is challenging the decision. Finally, foetal monitoring house HeraMED (ASX:HMD) has raised $1.98 million 1.2 cents a share, a 4.8% discount. Reporting latecomers: please wait to be seated Companies needed to lodge their quarterly reports within a month. But the ASX 'ushers' will still see them to their seats if they're not too late. The bourse on Friday suspended Syntara (ASX:SNT) for non-lodgment – but not for long. The myelofibrosis drug developer was allowed to resume trading, having lodged before the opening of Friday's trading. The quarterlies were due on Thursday. Syntara reported receipts of $78,000, cash outflow of $3.7 million and a $15 million cash balance. By the end of September, investors should expect final results from the company's phase II program that evaluated its drug candidate amsulostat, in 16 patients. An interim readout showed eight of 11 evaluable patients (73%) achieved a reduction of 50% or more in their myelofibrosis symptoms. Syntara awaits an FDA review of its application to start a follow-on phase II/III trial. Meanwhile, Syntara will seek shareholder approval to grant 4.769 million of incentive shares to CEO Gary Phillips, at nil consderation.
